| INTRODUC TI ON
The limited availability of suitable donor organs impedes transplantation as a curative therapy for heart failure. 1 The ventricular assist device (VAD) is increasingly used as a bridge to transplantation to increase survival while waiting for a compatible organ. VAD is effective in prolonging survival of patients with heart failure, enabling 70% of patients to bridge to subsequent heart transplant. 1 The effectiveness of VAD has led to increased use, with 19% of heart transplants in the United States between 2004 and 2014 bridged to transplant using VAD. Though VADs are an effective bridge therapy, they are associated with distinct complications that affect subsequent transplantation. In addition to complications associated with a major surgery such as bleeding and infection, there is a debated immunologic risk. VAD support has been associated with development of antibodies against HLA alloantigens. [2] [3] [4] [5] [6] [7] [8] The presence of anti-HLA antibodies has serious adverse consequences for patients awaiting heart transplantation. Antibodies against donor HLA class I and class II antigens are definitively associated with antibody-mediated rejection and allograft failure and associated with increased mortality. [9] [10] [11] [12] [13] Reported rates of alloimmunization following VAD placement are variable, ranging from 28% to 66% of patients. 2, 4, 14, 15 Transfusion of cellular blood products is known risk factors for HLA-allosensitization, with reported sensitization rates of 17%-15% for packed red blood cell (PRBC) units and 28%-55% for single-donor platelet (SDP) units. 16 Patients undergoing VAD surgery have a nearly universal exposure to blood products, receiving a median of 8 PRBCs and 2 SDPs. 6, [17] [18] [19] This provides ample exposure to alloantigens, though direct associations between blood product exposure and risk for development of alloantibodies in the setting of VAD remain elusive. 14, [20] [21] [22] However, reported rates of HLA alloimmunization associated with VAD are higher than for general transfusion, with reports of sensitization rates up to 66%. 2, 4, 14, 15 Similar effects have not been observed for extracorporeal membrane oxygenation, suggesting a unique effect of VAD to promote alloantibody formation. Given the undefined effects of VAD on alloimmunization, we investigated transfusion associated with VAD implantation with the goal of identifying risk factors for anti-HLA antibody formation.
| ME THODS

| Study population
Records for 164 adult patients undergoing heart transplantation (n = 107 patients undergoing VAD implantation as a bridge to transplantation, n = 57 non-VAD patients) at the University of California San Diego between January 2014 and September 2017 were retrospectively reviewed ( Table 1) . Transfusion data were available for all 164 heart transplant patients. Of the 107 VAD patients, both pre-VAD and subsequent post-VAD antibody data were available in 59 patients (n = 84 pre-VAD antibody data, n = 61 post-VAD antibody data). Electronic medical records and laboratory records were reviewed for perioperative (day 0-3 following VAD insertion) blood product utilization, and anti-HLA antibody testing (most recent pre-VAD placement and 2-12 weeks after VAD placement) and cellular crossmatch testing results.
Clinical records were reviewed for patient demographics and clinical events related to VAD implantation and heart transplantation.
All study procedures were conducted under the approval and supervision of institutional IRB.
| Anti-HLA antibody testing
All patient serum samples were collected and tested as part of standard of care treatment according to the existing protocols. Patients were screened for anti-HLA antibodies using FlowPRA Class I and Class II assays (One Lambda) using FACSCanto or FACSCalibur instruments (BD Biosciences). Anti-HLA antibodies detected by FlowPRA were identified using LABScreen Single Antigen HLA Class I and Class II bead assays using a Labscan 200 (Luminex). Data were analyzed using HLA Fusion software (One Lambda). Antibodies with normalized mean fluorescence intensity (MFI) ≥3000 were identified as positive, based upon likelihood of causing a positive flow cytometric crossmatch. 23 
| Cellular crossmatch testing
| Statistical analysis
Calculated PRA (cPRA) percentages were calculated entering all unacceptable antigens for HLA-A, -B, -C, -DR, and -DQ in the UNet 
| RE SULTS
| VAD placement results in increased anti-HLA antibodies
To examine the effect of VAD on sensitization against allogeneic HLA, we compared the incidence of anti-HLA antibodies in patients before (n = 84) and after VAD implantation (n = 61) ( Figure 1A ). The Figure 1B ). This resulted in a significant increase in risk for immunologic incompatibility with potential donors as measured by increased cPRA ( Figure 1C ). 
| Development of anti-HLA antibodies after VAD significantly delays subsequent transplantation
| Transfusion associated with VAD
Formation of antibodies against HLA alloantigens results from specific sensitizing events such as transplantation, transfusion, or pregnancy. Given the high degree of exposure to blood products associated with thoracic surgery for VAD placement, we sought to evaluate whether there is a product-specific or dose-dependent relationship between peri-VAD surgery transfusion and anti-HLA antibody formation. Review of transfusion records for all VAD patients demonstrated that 100/107 (93.5%) of patients received at least one PRBC or SDP unit temporally associated with VAD placement (defined as either during surgery or within 3 days after surgery).
Average transfusion support included 9.6 ± 9.9 total cellular blood products including 7.8 ± 9.1 PRBC units and 1.8 ± 1.9 SDP units ( Figure 3A) , similar to reported rates of transfusion associated with VAD placement. These data confirm the significant exposure risk for alloimmunization by transfusion in patients receiving VAD therapy.
To evaluate the risk of anti-HLA antibody formation associated 
| Factors influencing alloantibody formation
Given the absence of a dose-dependent correlation between cellular blood product transfusion and formation of anti-HLA antibodies, we next investigated patient-specific factors that could explain differential alloantibody formation ( Table 2 ). There were anti-HLA antibody formation (Figure 2 ), similar to effects in other studies. 6, 21 Thus, we sought to identify underlying risk factors that might enable risk stratification or risk avoidance measures.
Ventricular assist device-associated antibodies can be split into two categories, non-specific antibodies and HLA-specific alloantibodies. Production of non-specific antibodies associated with VAD has been attributed to bystander activation of B cells due to a "pro-inflammatory" environment caused by turbulent blood flow and reactivity to the VAD. Non-specific antibodies can cause positive reactions in cellular crossmatch and alloantibody immunoassays, though their clinical significance appears to be limited. 4, 5, 22, 24 Consistent with this, we observe non-specific antibodies as evidenced by high background in solid-phase immunoassays and cellular crossmatching, though the effects of these are limited by routine use of EDTA serum treatment in solid-phase immunoassay and DTT serum treatment in cellular crossmatch. Of greater concern are antibodies with definable specificities against allogeneic HLA which can mediate AMR and allograft loss. [9] [10] [11] [12] [13] Development of antibodies against allogeneic HLA requires sensitization against specific alloantigen. Alloimmunization can occur through pregnancy, transfusion of cellular blood products, or prior New positive anti-HLA antibodies after VAD implantation transplant. 16 Given the nearly ubiquitous exposure risk as well as the viability of blood product exposure as a modifiable risk factor, we investigated cellular blood product exposure at the time of VAD placement as a risk factor for development anti-HLA antibodies. Analysis of cellular blood product exposure for patients in our study did not reveal a relationship between exposure dose and risk of alloimmunization ( Figure 3 ). Direct association between cellular blood product exposure and development of antibodies following VAD implantation has proven similarly elusive in other studies for several reasons, including the nearly universal exposure to cellular blood products and variability in the origin and composition of cellular blood products (ie, leukoreduced or non-leukoreduced PRBCs, SDPs vs multi-donor platelet units, irradiated or non-irradiated units). The most suggestive of these studies have indicated a higher risk of allommunization in VAD patients resulting from platelets 20,21 and a decreased risk associated with leukoreduced PRBCs. 14,16,20,25. However, other studies saw no relationships between transfusion exposure and alloimmunization. 22 Comparison of previously studied risk factors for anti-HLA antibody incidence did not demonstrate significant differences between patients developing anti-HLA antibodies and those not developing antibodies related to gender, ethnicity, or type of VAD used ( Table 2) This suggests there may be factors that predispose some patients to form alloantibodies, in the context of VAD but also in a more general manner. Future studies identifying such factors would be of particular interest to facilitate focused risk reduction strategies as well as possibly identify actionable targets to inhibit alloimmunization. Given the absence of a well-defined association between cellular blood product exposure, VAD placement, and alloimmunization, it is likely prudent to continue with current best practice guidelines for general blood conservation in thoracic surgery 26 and exclusive use of leukoreduced PRBCs 27 to minimize potential risk for alloimmunization.
It is worth noting that primary outcomes in this study included anti-HLA antibody formation as well as time to transplant. We do not have complete post-transplant anti-HLA antibody and clinical outcomes data for this cohort, and were thus unable to analyze mortality and the incidence of antibody-mediated rejection.
Questions regarding the impact of pre-transplant alloimmunization on post-transplant outcomes are of interest for future study. We hypothesize that patients who are sensitized to alloantigens as a result of VAD therapy could be at risk for post-transplant donor-specific alloantibody formation and resulting higher morbidity and mortality. A recent study 28 reported the outcome of patients with high immunological risk defined by pre-transplant donor-specific antibodies that were managed with a post-transplant prophylactic strategy instead of desensitization. The results of our study suggest that it may be of interest to propose applying such a strategy to patients identified as "at risk" based on immunologic response to pre-transplant alloimmunization against non-donor-specific HLA.
